By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AB Science 

3, Avenue George V

Paris    75008  France
Phone: 33-(0)1-47200014 Fax: 33-(0)1-47202411



Company News
AB Science (AB.PA) Announces Initiation Of An Adaptive Design Phase II/III Study With Masitinib In Patients With Refractory Metastatic Ovarian Cancer 7/15/2015 10:37:44 AM
AB Science (AB.PA) Studies Banned in France Due to Side Effects 7/9/2015 6:37:56 AM
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015 9:13:47 AM
AB Science (AB.PA) : Positive Phase II Clinical Study Data Of Masitinib In Triple Negative Breast Cancer 3/13/2015 7:14:47 AM
AB Science (AB.PA) : Successful Completion Of Futility Test For Masitinib In Alzheimer's Disease 2/10/2015 7:46:11 AM
AB Science (AB.PA): Positive Phase 2 Clinical Study Data Of Masitinib In Second-Line Metastatic Stomach Cancer 2/3/2015 7:14:16 AM
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015 9:59:46 AM
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014 7:39:56 AM
AB Science (AB.PA): Web Conference On Masitinib In Asthma - Safety And Efficacy Update 12/1/2014 4:18:42 PM
AB Science (AB.PA) Advances Ultra-Selective SYK Kinase Inhibitor Into Full Preclinical Development 12/1/2014 10:36:10 AM